Achieved record annual revenue of $143.4 million in 2025, marking seven consecutive years of revenue growth. Reported record Adjusted EBITDA of $31.5 million for 2025. Generated substantial annual cash flow from operations of $24.4 million in 2025. Maintained a solid balance sheet with a Net Leverage Ratio of 0.52x and a Debt/Equity Ratio of 0.75x as of December 31, 2025. Patient Services segment contributed $86.5 million (60%) to total revenue, while Device Solutions contributed $56.9 million (40%) in 2025. Gross Margin improved to 56.0% in 2025 from 52.2% in 2024, and Adjusted EBITDA Margin increased to 21.9% from 18.8% over the same period. The company is expanding its specialized oncology therapy model into new areas like pain management and wound care, supported by strategic partnerships. An ERP upgrade project, launched in Q2 2024, incurred expenses of $0.7 million in 2024 and $2.6 million in 2025, with expected completion in Q1 2026. A $20 million stock repurchase program was renewed in May 2024, with $11.0 million of shares purchased as of December 31, 2025.